Riluzol effect on treatment of drug resistant obsessive obsessive compulsive disorder
Not Applicable
- Conditions
- Obsessive-compulsive disorder.Obsessive-compulsive disorder
- Registration Number
- IRCT20151103024853N5
- Lead Sponsor
- Deputy of research and technology developement
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Patients with known obsessive compulsive disorder by DSM-V criteria.
Not to use alcohol chronic.
The patient had no serious risk factor for respiratory apnea and pulmonary fibrosis and not be affected.
Between 18 to 65 years old
The individual should be treated with a maximum dose of SSRI for at least 6 months and scored 20 or higher on the Y-BOCS criterion.
The patient's liver transaminase should not be more than 5 times higher than normal.
Exclusion Criteria
Pregnancy and nursing; Patients with a history of memantine use.
Patients who do not sign the ethical consent form or refuse to continue to participate in the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient's score in Y-BOCS test. Timepoint: Before intervention, 4, 8 and 12 weeks after intervention. Method of measurement: the list of Riluzole adverse effects.
- Secondary Outcome Measures
Name Time Method